Study protocol; Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial (TRUST)
- David J. Stott1, 21Email author,
- Jacobijn Gussekloo2,
- Patricia M. Kearney3,
- Nicolas Rodondi4, 5,
- Rudi G. J. Westendorp6, 7,
- Simon Mooijaart8,
- Sharon Kean9,
- Terence J. Quinn1,
- Naveed Sattar10,
- Kirsty Hendry1,
- Robert Du Puy2,
- Wendy P. J. Den Elzen11,
- Rosalinde K. E. Poortvliet2,
- Jan W. A. Smit12,
- J. Wouter Jukema13,
- Olaf M. Dekkers8,
- Manuel Blum14,
- Tinh-Hai Collet15,
- Vera McCarthy16,
- Caroline Hurley17,
- Stephen Byrne18,
- John Browne3,
- Torquil Watt19,
- Douglas Bauer20 and
- Ian Ford9
© The Author(s). 2017
Received: 21 January 2017
Accepted: 27 January 2017
Published: 3 February 2017
Subclinical hypothyroidism (SCH) is a common condition in elderly people, defined as elevated serum thyroid-stimulating hormone (TSH) with normal circulating free thyroxine (fT4). Evidence is lacking about the effect of thyroid hormone treatment. We describe the protocol of a large randomised controlled trial (RCT) of Levothyroxine treatment for SCH.
Participants are community-dwelling subjects aged ≥65 years with SCH, diagnosed by elevated TSH levels (≥4.6 and ≤19.9 mU/L) on a minimum of two measures ≥ three months apart, with fT4 levels within laboratory reference range. The study is a randomised double-blind placebo-controlled parallel group trial, starting with levothyroxine 50 micrograms daily (25 micrograms in subjects <50Kg body weight or known coronary heart disease) with titration of dose in the active treatment group according to TSH level, and a mock titration in the placebo group. The primary outcomes are changes in two domains (hypothyroid symptoms and fatigue / vitality) on the thyroid-related quality of life questionnaire (ThyPRO) at one year. The study has 80% power (at p = 0.025, 2-tailed) to detect a change with levothyroxine treatment of 3.0% on the hypothyroid scale and 4.1% on the fatigue / vitality scale with a total target sample size of 750 patients.
Secondary outcomes include general health-related quality of life (EuroQol), fatal and non-fatal cardiovascular events, handgrip strength, executive cognitive function (Letter Digit Coding Test), basic and instrumental activities of daily living, haemoglobin, blood pressure, weight, body mass index and waist circumference. Patients are monitored for specific adverse events of interest including incident atrial fibrillation, heart failure and bone fracture.
This large multicentre RCT of levothyroxine treatment of subclinical hypothyroidism is powered to detect clinically relevant change in symptoms / quality of life and is likely to be highly influential in guiding treatment of this common condition.
Clinicaltrials.gov NCT01660126; registered 8th June 2012.
KeywordsSubclinical hypothyroidism Elderly Randomised controlled trial Levothyroxine Quality of life Thyroid disease
Subclinical hypothyroidism (SCH) is defined as an elevated serum thyroid-stimulating hormone (TSH) with normal serum levels of free thyroxine (fT4) and few or no hypothyroid symptoms . Between 8 and 18% of adults over 65 years have biochemical features of SCH, the prevalence being higher among women . SCH is a possible contributor to multiple problems in older age. From a biological point of view thyroid hormones have multiple pleiotropic effects, acting as an essential regulatory factor in numerous physiological systems, including the vascular tree and the heart , brain (including cognition and mood) , skeletal muscle and bone .
Subjects with SCH do not have the full symptom cluster of overt hypothyroidism; however they often report non-specific symptoms such as tiredness, dry skin, feeling cold, puffy eyes, constipation and cognitive problems . Muscle symptoms such as cramps, weakness and myalgia are more common in SCH than in euthyroid controls . Reduced exercise capacity in SCH may be due to impaired skeletal muscle function and increased oxygen requirements of exercise . SCH may also cause a low-grade anaemia . The most convincing epidemiological associations of SCH with disease states are with non-fatal and fatal coronary heart disease events .
In contrast to the epidemiological associations with poor health found in the whole population, SCH in very old subjects (≥85 years) might be associated with better health and survival compared to the euthyroid state, giving rise to the possibility of an age interaction for thyroid hormone effects .
The pituitary-thyroid axis is an evolutionary selected key regulator to optimize developmental processes and physiological responses to environmental stress. At the same time TH might have a major role in the settlement of the life-history trade-off between growth, metabolism, and inflammation axes, which is required for homeostasis maintenance. It is therefore feasible that survival beyond the reproductive phase is better off with lower levels of thyroid hormone signalling, away from the optimal characteristics that are generally required in the reproductive part of life, with a lower rate of aging as a result. Several experimental animal models are in agreement with this hypothesis .
Evidence is lacking about the benefits of levothyroxine replacement in the elderly with SCH, as no large RCT on the full range of relevant clinical outcomes have been performed . The Cochrane systematic review of levothyroxine replacement for SCH summarised the evidence from RCTs up to 2006 . It concluded that there was some evidence for improved cardiac function and blood lipids with levothyroxine replacement, but a lack of data for improved survival, reduced cardiovascular morbidity or improved health-related quality of life; data were available for only 350 patients in 12 RCTs, often of short duration (range 6–14 months).
Subsequent RCTs of levothyroxine as an intervention for patients with SCH (excluding during pregnancy) have not resolved the clinical uncertainty, with generally small and underpowered studies [4, 14–25]; the largest sample size was 120 patients , and the longest mean follow-up 14 months .
We are conducting a large RCT with power to detect clinically worthwhile benefits from levothyroxine replacement for SCH. Critical elements of the study design include recruitment of subjects with persisting SCH (excluding those in whom it is a temporary phenomenon, who are less likely to benefit), long-term follow-up, and a range of clinically important outcomes.
The primary outcomes are changes in 2 domains (hypothyroid symptoms and fatigue / vitality) on the thyroid related quality of life questionnaire (ThyPRO)  at 1 year (minimum follow-up). Secondary outcomes include general health-related quality of life (EuroQol) , fatal and non-fatal cardiovascular events, handgrip strength , executive cognitive function (Letter Digit Coding Test) , basic  and instrumental activities of daily living , haemoglobin, blood pressure, weight, body mass index and waist circumference. Patients are monitored for specific adverse events of interest including incident atrial fibrillation, heart failure and bone fracture. The study will also be used to establish a blood bio-bank, to be used in future research into causes and mechanisms of health, disease and disability in older people with SCH.
Does Levothyroxine treatment for SCH give multi-modal benefits for older people with SCH?
Are benefits seen across a wide range of outcomes, including prevention of cardiovascular disease, and improving health-related quality of life, muscle function and cognition?
Are benefits seen in specific subgroups of older people with SCH, including women, very elderly and those with mild degrees of SCH (TSH 4.6–10 mU/L)?
Are any benefits offset by adverse effects, such as atrial fibrillation or heart failure?
This manuscript represents the content of protocol version 6.1, 24th March 2016.
This is a randomised double-blind placebo-controlled parallel group trial of levothyroxine for older people with SCH, with a minimum 1 year of follow-up.
The trial is running in four countries (UK, Ireland, the Netherlands and Switzerland). Potential subjects are identified from clinical laboratory databases and recruited from the community, aged ≥65 years with SCH, diagnosed on the basis of persistently elevated TSH levels (4.6–19.9 mU/L) with fT4 within the reference range. Baseline and follow-up TSH was measured by clinical laboratories affiliated with each clinical centre. TSH is measured on a minimum of two occasions at least three months apart, over a maximum period of 3 years. All subjects gave individual informed consent to participate (See Appendix 1 and 2; Additional files 1 and 2 for model patient information sheet and consent forms).
Subjects currently prescribed Levothyroxine, anti-thyroid drugs, amiodarone or lithium.
Recent thyroid surgery or radio-iodine (within 12 months).
Grade IV NYHA heart failure.
Clinical diagnosis of dementia.
Recent hospitalisation for major illness or elective surgery (within 4 weeks).
Recent acute coronary syndrome, including myocardial infarction or unstable angina (within 4 weeks).
Acute myocarditis or pancarditis.
Untreated adrenal insufficiency or adrenal disorder.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
Subjects participating in ongoing RCTs of therapeutic interventions (including Clinical Trials of Investigational Medicinal Products; CTIMPs).
Plan to move out of the region in which the trial is being conducted within the next 2 years.
Subjects are allocated to levothyroxine or placebo (1:1) with stratification by national site, sex and starting dose, using the method of randomly permuted blocks. The randomisation schedule is prepared by the data centre (Robertson Centre, Glasgow), independent of the clinical investigators. Implementation of the random allocation sequence is by an independent party, Mawdsley Brooks UK, who are responsible for packaging and labelling of the Investigational Medicinal Product (IMP) and masked to all other participant characteristics.
Enrolment of participants is done by study nurses, under the supervision of a medically trained principal investigator at each site. Allocation of study number is performed by central computer, with the decision triggered by the study nurses using a dedicated study website, following entering of eligibility data on an electronic clinic record form.
The IMP’s in this study are levothyroxine 25 and 50 micrograms tablets and identical placebo tablets for oral use. The tablets are white and round in shape with the tablet strength imprinted on the active and matched placebo tablets. All tables are identical in taste and smell. The tablets are manufactured and placed in blister strips by the supplier Merck, in accordance with Good Manufacturing Practice; distribution to national study sites is provided by Mawdsley Brooks UK.
The intervention starts with levothyroxine 50 micrograms daily (reduced to 25 micrograms in subjects <50Kg body weight or if known coronary heart disease – previous myocardial infarction or symptoms of angina pectoris) versus matching placebo for 6–8 weeks. Patients are advised to take their prescribed dose once daily in the morning before breakfast.
TSH <0.4 mU/L: treatment dose reduced to 25 micrograms levothyroxine in those starting on 50 micrograms; reduced to 0 in those starting on 25 micrograms – blinding maintained by giving placebo matching the 25 micrograms dose; these patients will have a further check TSH after 6–8 weeks; if TSH remains <0.4 mU/L patient will be withdrawn from randomised treatment.
TSH ≥0.4 and <4.6 mU/L: no change to the treatment dose; patient to be reviewed at 12 months.
TSH remains elevated (≥4.6 mU/L): additional 25 micrograms levothyroxine, giving a total daily dose of 75 micrograms levothyroxine for those starting on 50 micrograms, or a total daily dose of 50 micrograms levothyroxine for those starting on 25 micrograms.
Titration of dose of levothyroxine (25 micrograms increments) against serum TSH is repeated up to a maximum of two occasions, at 6–8 week intervals, with a check of serum TSH performed at 6–8 weeks after all dose titrations. The investigators remained masked to the results of TSH measurements throughout the course of the study.
The above process (but with only a single up-titration) is repeated at 12 months (plus or minus 1 month) then annually (at 24 and 36 months plus or minus 1 month). The maximum possible dose of levothyroxine that is prescribed is 150 micrograms.
A mock titration (by computer algorithm) is performed in the placebo group aiming for approximately the same frequency as that likely to be required in the levothyroxine-treated group. We have adopted an adaptive schedule, in which the data centre allocates the same proportion of placebo patients to have dose adjustment (up and down) as are required in the levothyroxine group. This ensures that the burden of assessment, and number of tablets to be taken, is the same in both the levothyroxine and placebo groups. The computer generated allocation also ensures that the clinical investigators remain blind to treatment allocation.
Where a proposed up-titration of levothyroxine (or placebo) is thought to be clinically inappropriate (e.g. known non-adherence to IMP, recent major illness) the algorithm is manually ‘over-ridden’ and the patient is not up-titrated.
If overt biochemical hypothyroidism is identified (TSH ≥20 mU/L), the data centre requires a second TSH measurement with fT4 within two weeks; if overt biochemical hypothyroidism is confirmed (fT4 below reference range), the patient is required to stop the trial medication and recommended to attend GP for consideration of open treatment with levothyroxine.
If biochemical hyperthyroidism (TSH < 0.4 mU/L) develops in the placebo group, or occurs at two consecutive follow-up visits in a patient in the levothyroxine group; i.e. persisting despite down-titration of the levothyroxine dose, the patient will stop the trial medication and attend their GP for consideration of further assessment and treatment of hyperthyroidism.
The study is double blinded. Subject blinding to treatment allocation is ensured through use of matched tablets for levothyroxine and placebo, with a mock titration in the placebo group (see above under intervention for details). Clinician and study centre blinding to treatment allocation is ensured by remote laboratory analysis of blood samples for TSH and dose titration as per computer algorithm.
All blood tests for in-study TSH and fT4 levels are performed by the research team without knowledge of the results; all results from the follow-up phase of the study are forwarded directly to the data centres who advise the clinical research team on any dose titration. The clinical research team are not informed of the results of thyroid function testing. The same process of blinding is followed for measurement of haemoglobin on a full blood count.
If the clinical investigator or attending physician deems that unblinding is necessary they will have 24-hr access to telephone unblinding through the data-centre. In the event of a SUSAR, the sponsor (but not the investigators) will be unblinded to facilitate reporting to the relevant regulatory authorities including the MHRA.
Descriptive study data and outcome measures
Age, sex and race.
Lifestyle; smoking, alcohol intake.
Known cardiovascular disease, including history of coronary heart disease (angina pectoris or previous myocardial infarction), cerebrovascular disease (ischaemic stroke, transient ischaemic attack) or peripheral vascular disease (intermittent claudication), or any revascularisation procedure for ischaemic vascular disease; history of atrial fibrillation (AF); epilepsy; hypertension; diabetes mellitus; osteoporosis.
Prescribed medicines and over-the counter aspirin or non-steroidal anti-inflammatory drugs will be recorded at each study visit; medicine count will be used as an assessment of baseline co-morbidity.
Mini-mental state examination (MMSE) score  will be recorded at study baseline as a descriptor of general cognitive function. However it will not be repeated or used as an outcome measure as it is insensitive to change over the time-span planned for this study.
Home support services (e.g. home help, meals-on-wheels, district nursing) and home circumstances (e.g. living alone, co-habiting, standard or sheltered housing, or entry to care home), at study baseline and final review.
Primary study outcomes:
Initial plans were for joint primary study outcomes of thyroid-specific quality of life and of incident cardiovascular events. However, due to lower recruitment than initially planned, the study is underpowered to detect an effect on incident cardiovascular events and a formal modification to protocol (including on the registered trial protocol at clinicaltrials.gov) has been made to designate this as a secondary outcome.
Therefore the primary outcomes for the study are thyroid-related quality of life and symptom burden as measured by the ThyPRO hypothyroid symptoms score and fatigue / vitality score measured at study baseline, 6–8 weeks and 12 months post-recruitment and at final review . The primary outcome is the change in the score between baseline and one year. For disease-specific and general quality of life, greatest effect will be expected after 1 year of treatment, and for these endpoints this will be the primary time-point for analysis. In a systematic review of thyroid related quality of life assessments ThyPRO was recommended as an appropriate assessment tool for benign thyroid diseases .
General health-related quality of life (EuroQol-5D, including the EuroQol visual anologue scale) . Measured at study baseline, 6–8 weeks and 12 months post-recruitment and at final review.
Comprehensive thyroid quality of life assessment ThyPRO-39  - recorded at final follow-up.
Fatal and non-fatal cardiovascular events (acute myocardial infarction; stroke; amputations for peripheral vascular disease; revascularisations for atherosclerotic vascular disease, including for acute coronary syndrome, and heart failure hospitalisations).
Total mortality and cardiovascular mortality.
Handgrip strength  (Jamar isometric dynamometer - best of 3 measures in dominant hand). Measured at study baseline, 12 months and at final review.
Executive cognitive function (letter digit coding test; LDCT) . Measured at study baseline, 12 months and at final review.
Functional ability (basic Activities of Daily Living (ADL) measured using Barthel Index [BI] ; instrumental activities of daily living  measured using the older American resources and services [OARS] tool) . Measured at baseline and final follow-up.
Haemoglobin measured on a full blood count at baseline and 1 year.
Blood pressure (systolic and diastolic). Measured at screening / baseline, 12 months and at final review. Measurements were made using an Omron 705IT, after a minimum of 3 min sitting, using a standard cuff (12–13 cm long and 35 cm wide) unless the arm is very small or large, when an appropriate alternative cuff size is determined by visual assessment.
Weight, waist circumference and body mass index. Height, weight and waist circumference are measured at screening / baseline; weight and waist circumference are repeated at 12 months and at final review.
Report forms for possible cardiovascular endpoints and SAEs are generated for the study nurses to complete; these are entered via the trial web portal which has an in-built notification to the Endpoints Committee. Adjudicated endpoints are entered via the trial web portal using separate adjudication record forms. Anonymised source documents are uploaded by the study nurses via the trial web portal, to assist in the adjudication process, in accordance with the committee’s requirements.
Drug accountability data is gathered for each patient including distribution date, quantity of study drug supplied, and drug supply returns including date, and quantity of tablets returned.
Blood samples for the study biobank are collected at baseline (40 ml venous blood) and at the 1 year visit (10mls venous blood). Baseline bloods are stored in 0.75 ml aliquots as follows - 3 EDTA plasma, 1 whole blood, 8 serum, 2 citrated plasma, 1 NaF plasma, 1 buffy coat, 3 heparin plasma; total: 19 aliquots per patient at baseline. One year bloods are stored in four 0.75 ml serum aliquots per patient.
The TRUST biobank is the communal property of the TRUST Executive Committee. The TRUST biobank is organised through the TRUST Executive Committee by the TRUST Biobank Committee. The TRUST Biobank Committee has a representative from each TRUST site and is approved by the TRUST Executive Committee. The partners in this collaboration are the partners associated with the trial’s principal investigators in Glasgow (Scotland), Cork (Ireland), Bern (Switzerland), and Leiden (Netherlands). All TRUST partners agree to the principles outlined below in order to permit the optimum information to be gained from exploitation of the Biobank.
The central location of the TRUST biobank is at the Department of Clinical Chemistry of Leiden University Medical Centre (LUMC), the Netherlands. The TRUST biobank consists of (1) all plasma, serum and DNA samples from randomised TRUST participants held either in the main biobank depository at LUMC or in the local laboratories where TRUST samples are handled during the study and (2) all data derived from analyses of these samples.
The Department of Clinical Chemistry of the LUMC is fully accredited by the Dutch Co-ordinating Committee for Quality Control of Laboratories in Health Care. Through the LUMC Department of Clinical Chemistry, the TRUST biobank adheres to all quality assurance standards that are necessary for a biobank. Furthermore, for all legal issues the TRUST biobank adheres to local (LUMC) and national guidelines. These guidelines cover donor rights, re-identification of donors, and process for removing samples from the biobank if a donor revokes consent.
Access to the material of the biobank is gained by submitting a proposal in writing to the chair of the Biobank Committee (PK). The chair will communicate the proposal to the other members of the Biobank Committee and together they will send a written proposal to the TRUST Executive Committee. Once the proposal is approved by the TRUST Executive Committee, the operational aspects of obtaining material will be handled by the Biobank group.
Study recruitment and sample size justification
In the initial study plans we aimed to recruit 3000 community dwelling subjects aged 65 years or over with SCH. However due to a combination of factors we were unable to achieve this number; these included substantial delays in starting the study due mainly to difficulties in procuring suitable supplies of levothyroxine and matching placebo. Study recruitment targets were revised (October 2014; by when 290 patients randomised) with an anticipated minimum of 540 to be randomised; with an upscaling of geographical areas for recruitment in all countries we anticipated an increase up to a maximum of 750 patients randomised. Given the projections for recruitment, revised power calculations were calculated for minimum total recruitment number of 540 and a maximum number of 750.
Hypothyroid symptom and fatigue / vitality domains from the Thyroid-related Quality of Life patient-reported outcome measure (ThyPRO)  are our efficacy outcomes, and are given equal weights as co-primary outcomes, with the required p-value for statistical significance split equally to each (0.05/2 = 0.025 to each test). We assumed SDs for data at 1 year values (adjusted for baseline) of 13.3 and 18.3 (on 100-point scales) for hypothyroid and fatigue / vitality scales respectively. These SDs were justified on the basis of an interim analysis of data on the 8th of January 2015. We calculated 80% power to detect a change with Levothyroxine treatment (versus placebo) of 3.5 or 3.0 points on the hypothyroid scale and 4.9 or 4.1 points on the fatigue / vitality scale with total sample sizes of 540 or 750 respectively. Personal communication from the author of ThyPRO (Torquil Watt) indicated that a 9 point change (100 point scale) would be a realistic and clinically meaningful effect size.
Retention of recruits was facilitated by offering flexibility in location of follow-up, and reasonable time windows (plus or minus 1 month for the 12 month and subsequent reviews) for review. Where patients elected to withdraw from active treatment they were offered follow-up, with recording of all study outcomes.
Data and statistical analysis
The data centre for the study is based in the Robertson Centre for Biostatistics at the University of Glasgow. This sits in the Glasgow Clinical Trials Unit, a UK Clinical Research Collaboration fully registered Clinical Trials Unit. The Centre has an ISO 9001/2008 quality management system and TickIT, the corresponding standard for software development.
The statistical analysis plan is presented as an Additional file 3. Data will be summarised overall and by treatment group. Continuous variables will be summarised as number of observed values, number of missing values, mean and standard deviation, median and interquartile range and minimum and maximum. Categorical data will be summarised as number of observed values, number of missing values, number and percentage in each category.
Continuous efficacy outcomes involving measurement at follow-up and baseline will be analysed at each time point comparing treatment groups and adjusting for stratification variables and baseline levels of the same variable using linear regression. In addition, data items measured at more than one follow-up time will be analysed using repeated measures regression analyses and in terms of the final assessment for each participant. Continuous efficacy outcomes measured at final follow-up only will be compared between treatment groups using linear regression adjusting for stratification variables (site, sex and starting dose of levothyroxine).
For all efficacy outcomes measured at baseline and final visit, additional exploratory analyses that adjust for time from baseline to final visit will be carried out. Distributions of the residuals will be reviewed and will be taken into consideration in assessing whether or not additional analyses based on transformations should be carried out. When calculating ThyPRO scores, valid raw total scores containing missing items will be scaled so that the maximum possible score is maintained.
Time-to-event outcomes will be compared between groups using Cox proportional hazards regression models adjusting for stratification variables. Time to event curves will be based on the Kaplan-Meier method.
All efficacy analyses will be carried out on the intention to treat (ITT) population. Safety analyses will be carried out on the ITT population. The main analyses will be modified ITT based on participants with data on the outcome of interest. These analyses will be supported with sensitivity analyses using mixed effects models and multiple imputations. Primary and secondary analyses will be repeated on the per protocol population as exploratory analyses.
○ <10 / ≥10
○ <7 / 7–9.99 / ≥10
In addition, continuous interactions with age at randomisation and baseline TSH will be analysed analogously.
Study outcome analyses will be repeated on the per protocol population as exploratory analyses.
Patient safety and adverse event recording
We have taken particular care in devising a titration algorithm to avoid any possibility of prolonged periods of thyroid hormone over replacement in those allocated to levothyroxine. This should substantially reduce the risks of adverse effects such as atrial fibrillation or cardiac failure. In epidemiological studies these problems are observed in association with biochemical hyperthyroidism and not with TSH within the reference range. Similarly for those allocated to placebo we have developed an algorithm that is designed to detect those who develop overt hypothyroidism are require to start open-label levothyroxine. These measures are designed to ensure safety of those who are randomised into the trial.
Within ThyPRO we are assessing the domain of hyperthyroid symptoms as a possible adverse effect (recorded at baseline, 6–8 weeks, 12 months and final visit).
Adverse events (AEs) are recorded, notified, assessed, reported, analysed and managed in accordance with the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended). Certain potential adverse events are anticipated or likely as a result of the study and study population. The adverse events detailed below are likely to occur in the context of over replacement of levothyroxine. Our dose titration scheme and study processes of careful monitoring of thyroid function tests are designed to ensure we avoid prolonged periods of thyroid hormone excess.
Full details of all AEs of special interest (new atrial fibrillation, heart failure, fractures, new diagnosis of osteoporosis) including the nature of the event, relationship to study drug and outcome are recorded in the electronic case report form. AEs of special interest are monitored and followed up until satisfactory resolution or stabilization.
Atrial fibrillation (AF)
AF is associated with subclinical hyperthyroidism  and therefore is a potential risk of thyroid over-replacement for SCH. It should not occur if TSH is maintained in the normal range, however we pay particular attention to identifying this possible adverse event.
Cardiac rhythm is determined at study baseline, and new onset AF, paroxysmal or persisting, is diagnosed from an annual single-lead electrocardiograph, or if noted on 12-lead electrocardiograph or telemetry performed as part of hospitalisation or other clinical care, or if identified by inquiry about hospitalisations and out-patient visits (at all patient contacts). This general process of screening for atrial fibrillation has been found to be very sensitive for identifying new cases .
We use a single-lead recorder (Omron HeartScan HCG-801-E). This provides a simple and quick assessment of cardiac rhythm; it has been shown to have high diagnostic accuracy for AF (sensitivity 99%, specificity 96%) compared to a standard 12-lead electrocardiograph .
Prevalent heart failure and incident heart failure diagnosis / hospitalisations will be recorded, as this outcome is a potential risk of thyroid dysfunction and of thyroid hormone over replacement .
Musculoskeletal effects of Levothyroxine are described, including osteopenia/ osteoporosis . We record all new fractures and all new diagnoses of osteoporosis. Formal screening for osteoporosis is not required for this trial.
Study monitoring and auditing
Study monitoring visits are conducted according to a study-specific monitoring plan devised by NHS Greater Glasgow and Clyde and subsequent monitoring reports are reviewed by NHS Greater Glasgow and Clyde. At a minimum, each site was monitored before the study commenced (Study Initiation), study visit(s) and at the end of the trial (Study Close Out Visit). Additional monitoring visits were undertaken if required and the study was subject to routine or for-cause audit visits. Investigators and site staff were notified in advance of any audit and/or monitoring visits. Sponsors out-with the UK identified the level of monitoring required and developed a monitoring plan, informed by the UK monitoring plan.
Committees, role of sponsor / funder
The committee structure for the study included the following. The main decision making group for the study is an Executive group of principle investigators (PIs) (Chair Professor David J Stott; members Professor Ian Ford, Professor Jacobijn Gussekloo, Professor Patricia M Kearney, Dr Nicolas Rodondi, Professor Rudi GJ Westendorp). The strategic planning and conduct of the study is supervised by a Steering Committee (Chair Professor David J Stott) which included the above PIs, plus key ancillary partners; the PIs approved additional members of the steering committee as required through the study. This committee provided a discussion forum for information to be shared, and opportunity given to influence the conduct of the study. National organising committees (chaired by the national PIs) supervised the conduct of the trial in each of the 4 participating countries.
The trial is subject to supervision by an Independent Data Monitoring Committee (IDMC). Members are Professor Gary Ford (Chair; Chief Executive Officer of the Oxford Academic Health Science Network, Oxford), Professor Thompson G Robinson (University Hospitals of Leicester NHS Trust, Department of Cardiovascular Sciences, Leicester Royal Infirmary, Leicester), Professor Colin Dayan (Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Heath Park, Cardiff), Professor Kathleen Bennett (Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James’s Hospital, Dublin). The primary responsibility of the IDMC is to assess safety data in order to protect the ethical and safety interests of the subjects recruited into the study, while safeguarding, as far as possible, the scientific validity of the study. The IDMC reviews information on the progress of the trial and selected safety and efficacy data accruing from the trial, but may request additional data if considered necessary in order to support the assessment of relative risk and benefit within the study.
To provide independent and unbiased review of clinical endpoint events which occur during the study.
To ensure unified and unambiguous events evaluation practices across the study, through application of standardised event criteria, per protocol specifications.
To compensate for regional diversity in medical practice in the area of endpoint evaluation and classification, thereby reducing the impact of this diversity.
This includes review and classification of all: causes of death, strokes, myocardial infarctions, heart failure hospitalisations, which are identified as potential clinical endpoints.
The classification of endpoints is based on data from a case report form and appropriate source documents. The EPC is blinded to treatment allocation.
There is a TRUST Biobank committee consisting of Professor Patricia M Kearney (chair), NS, H Anette van Dorland (Berne, Switzerland), WPJdenE. This committee advises the steering committee on storage and usage of the TRUST biobank.
The primary co-sponsors of the study are NHS Greater Glasgow and Clyde and University of Glasgow.
Prior to study initiation, a non-commercially funded clinical trial co-sponsorship agreement was put in place between NHS Greater Glasgow and Clyde and University of Glasgow. The role and liabilities each organisation will take under Clinical Trials Regulations, 2004 (SI 2004:1031) are laid out in this agreement signed by both organisations. The University of Glasgow is responsible for carrying out the obligations and responsibilities set out in the aforementioned agreement, and shall be deemed “sponsor” for the purposes of Part 3 of the regulations in relation to the study. NHS Greater Glasgow and Clyde shall be responsible for carrying out the obligations and responsibilities set out in the agreement, and shall be deemed “sponsor” for the purposes of Parts 4, 5, 6 and 7 of the regulations in relation to the study.
Each participating member/associated state has designated a legal entity to operate as national sponsor. The UK co-sponsors delegate sponsor responsibilities to each identified legal entity and this is defined in a ‘Research Agreement for the performance of an intergroup clinical trial’. A fully executed agreement was implemented with each participating member/associated state prior to the TRUST study starting in that country. The sponsors were responsible for ensuring appropriate indemnity and insurance is in place to cover the liabilities arising from trial conduct and participation. The sponsors of the study take no role in the preparation or approval of scientific outputs from this trial.
Merck KGaA have supported the study by providing (free of any cost or charges) the medication, in form of levothyroxine 50 microgram and 25 microgram tablets and matching placebos. All supplies are manufactured in accordance with current Good Manufacturing Practice and in accordance with EU Directive 2001/20/EC. Merck KGaA reserve the right to ask for deletion of any Merck confidential information. The views and opinions described in this paper do not necessarily reflect those of Merck KGaA.
We are in a strong position to ensure effective dissemination of the results of the TRUST study, including early adoption into clinical practice. The patient advocacy group Thyroid Federation International will play a key role in planning the dissemination strategy and approving outputs to ensure methods and content fit with the public need. Publications are approved through the Steering Committee which involves representatives from all partner organisations. It is anticipated that the main study results will be announced at the Endocrine Society Meeting in Orlando 1-4th April 2017.
We have a strategy for informing participant patients and their general health care practitioners. At the final visit we determine what information the patient wishes to receive about their treatment in the study. Communication to the patient and GP about individual treatment is made normally within 15 working days after completion of the close-out visit. Information provided for the patient’s health care practitioner will include treatment allocation, final dose (if on levothyroxine) and TSH level at final visit. Unblinding of patient and their health care practitioner requires either a member of the study team or an independent medical advisor to be unblinded in the course of release of information; these person(s) are not involved in any way in measurement or recording of study endpoints or subsequent adjudication of SAEs (including gathering information or adjudication), either as possible vascular events or as events that are being considered for expectedness or severity for the MHRA or equivalent regulatory authority. This minimises the risk of observer bias and ensure the integrity of study data on SAEs is preserved.
We will provide access to the overall results of the study and explain implications for clinical practice to participating patients and for their health care practitioners, with national stakeholder meetings in country for supporting clinicians and patients; we also will announce the results using a study website. We aim for these communications about the results of the study to be within 1 month of the primary publication.
The TRUST trial is the first large-scale multicentre RCT of treatment of older people with SCH, comparing levothyroxine with matching placebo. The study will contribute substantially to knowledge on treatment of SCH in older people, with good statistical power to detect a meaningful effect on symptoms and thyroid-related health-related quality of life. We anticipate the main study results will be published in the Spring of 2017.
Intention to treat
Letter digit coding test
Mini-mental state examination
Randomisation controlled trial
Serious adverse event
Thyroid-related quality of life measure
Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial
Serum thyroid-stimulating hormone
Supplies of levothyroxine and matching placebo (in blister packs) were provided free of charge by Merck KGaA.
Implementation of the randomisation schedule, packaging and labelling of medicines, and distribution to national study sites was performed by Mawdsley Brooks (UK).
The authors are grateful to Yvonne Andersson Lakwijk, of Thyroid Federation International, who provided constructive comments on the protocol and conduct of the study from the patient perspective.
Joanne McGarry, Academic Research Coordinator, NHS Greater Glasgow and Clyde, Clinical Research and Development Central Office West Glasgow Ambulatory Care Hospital Dalnair Street Glasgow G3 8SW, Email: email@example.com, Tel: +44 (0)141 232 1818
The study was supported by a research grant from the European Union FP7-HEALTH-2011 programme - Investigator-driven clinical trials for therapeutic interventions in elderly populations. Grant agreement number 278148. The funder takes no role in the preparation or approval of scientific outputs from this trial.
Availability of data and materials
We welcome proposals for collaborative use of the study data, once planned publications of the study data have been completed. Any proposal must be consistent with the consent provided by the study participants and any relevant information governance and ethical requirements. Costs of preparing any datasets, and any related data transfer agreements or of conducting statistical analyses will have to be met by proposers. Proposals should be sent to the trial Steering Committee.
All authors have fulfilled the following: 1. made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2. been involved in drafting the manuscript or revising it critically for important intellectual content; 3. given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and 4. agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Additional specific contributions by author; DJS – Lead on conception and design of the work; and interpretation of data for the work; AND Lead in finalising the manuscript. JG – Primary investigator and National lead for Netherlands. PMK - Primary investigator and National lead for Ireland. NR - Primary investigator and National lead for Switzerland. RGJW - Primary investigator and lead for Leiden Academy Vitatality and Ageing, Netherlands. IF – Director of Clinical Trials Unit, University of Glasgow. DJS (lead), JG, PMK, NR, RGJW, SK, SM, TJQ, NS, JWJ, JB, JWAS, OMD and IF were all named co-applicants on the original EU-FP7 grant application.
Merck KGaA supported the study by providing (free of any cost or charges) the medication. Merck KGaA played no role in the design or funding of the study.
There are no other competing interests to declare.
Consent for publication
Not applicable. The manuscript does not contain data from any individual person.
Ethics approval and consent to participate
For the UK the study was approved by the Multicentre Research Ethics Committee (A) and the MHRA, with co-sponsors NHS Greater Glasgow and Clyde and the University of Glasgow. For the Netherlands, the study was approved by the Medical Ethical Committee on Research Involving Human Subjects (CCMO). In Switzerland, the study was approved by the Bern and Lausanne ethical boards and by Swissmedic, the Swiss competent authority for drugs. In Ireland, the study was approved by the Clinical Research Ethics Committee, Cork and by the Health Products Regulatory Authority (formerly known as the Irish Medicines Board).
Protocol amendments were harmonised across all countries, initiated by the chief investigator and national study leads, with revised forms submitted to the relevant approving bodies through each national sponsor.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Surks MI, Ocampo E. Subclinical thyroid disease. Am J Med. 1996;100(2):217–23.View ArticlePubMedGoogle Scholar
- Baumgartner C, Blum MR, Rodondi N. Subclinical hypothyroidism: summary of evidence in 2014. Swiss Med Wkly. 2014;144:w14058.PubMedGoogle Scholar
- Monzani F, Di Bello V, Caraccio N, Bertini A, Giorgi D, Giusti C, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab. 2001;86(3):1110–5.View ArticlePubMedGoogle Scholar
- Parle J, Roberts L, Wilson S, Pattison H, Roalfe A, Haque MS, et al. A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. J Clin Endocrinol Metab. 2010;95(8):3623–32.View ArticlePubMedGoogle Scholar
- Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015;313(20):2055–65.View ArticlePubMedPubMed CentralGoogle Scholar
- Javed Z, Sathyapalan T. Levothyroxine treatment of mild subclinical hypothyroidism: a review of potential risks and benefits. Ther Adv Endocrinol Metab. 2016;7(1):12–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Reuters VS, Teixeira Pde F, Vigario PS, Almeida CP, Buescu A, Ferreira MM, et al. Functional capacity and muscular abnormalities in subclinical hypothyroidism. Am J Med Sci. 2009;338(4):259–63.View ArticlePubMedGoogle Scholar
- Lankhaar JA, de Vries WR, Jansen JA, Zelissen PM, Backx FJ. Impact of overt and subclinical hypothyroidism on exercise tolerance: a systematic review. Res Q Exerc Sport. 2014;85(3):365–89.View ArticlePubMedGoogle Scholar
- Bremner AP, Feddema P, Joske DJ, Leedman PJ, O’Leary PC, Olynyk JK, et al. Significant association between thyroid hormones and erythrocyte indices in euthyroid subjects. Clin Endocrinol (Oxf). 2012;76(2):304–11.View ArticleGoogle Scholar
- Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365–74.View ArticlePubMedPubMed CentralGoogle Scholar
- Bukvic BR, Zivaljevic VR, Sipetic SB, Diklic AD, Tausanovic KM, Paunovic IR. Improvement of quality of life in patients with benign goiter after surgical treatment. Langenbeck’s Arch Surg. 2014;399(6):755–64.View ArticleGoogle Scholar
- Dehghan A, Bis JC, White CC, Smith AV, Morrison AC, Cupples LA, et al. Genome-wide association study for incident myocardial infarction and coronary heart disease in prospective cohort studies: The CHARGE Consortium. PLoS One. 2016;11(3):e0144997 (no pagination).View ArticlePubMedPubMed CentralGoogle Scholar
- Villar HC, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev. 2007;3:Cd003419.Google Scholar
- Duman D, Demirtunc R, Sahin S, Esertas K. The effects of simvastatin and levothyroxine on intima-media thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective, randomized-controlled study. J Cardiovasc Med (Hagerstown). 2007;8(12):1007–11.View ArticleGoogle Scholar
- Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab. 2007;92(5):1715–23.View ArticlePubMedGoogle Scholar
- Mikhail GS, Alshammari SM, Alenezi MY, Mansour M, Khalil NA. Increased atherogenic low-density lipoprotein cholesterol in untreated subclinical hypothyroidism. Endocr Pract. 2008;14(5):570–5.View ArticlePubMedGoogle Scholar
- Teixeira PF, Reuters VS, Ferreira MM, Almeida CP, Reis FA, Melo BA, et al. Treatment of subclinical hypothyroidism reduces atherogenic lipid levels in a placebo-controlled double-blind clinical trial. Horm Metab Res. 2008;40(1):50–5.View ArticlePubMedGoogle Scholar
- Cinemre H, Bilir C, Gokosmanoglu F, Bahcebasi T. Hematologic effects of levothyroxine in iron-deficient subclinical hypothyroid patients: a randomized, double-blind, controlled study. J Clin Endocrinol Metab. 2009;94(1):151–6.View ArticlePubMedGoogle Scholar
- Mainenti MR, Vigario PS, Teixeira PF, Maia MD, Oliveira FP, Vaisman M. Effect of levothyroxine replacement on exercise performance in subclinical hypothyroidism. J Endocrinol Invest. 2009;32(5):470–3.View ArticlePubMedGoogle Scholar
- Nagasaki T, Inaba M, Yamada S, Shirakawa K, Nagata Y, Kumeda Y, et al. Decrease of brachial-ankle pulse wave velocity in female subclinical hypothyroid patients during normalization of thyroid function: a double-blind, placebo-controlled study. Eur J Endocrinol. 2009;160(3):409–15.View ArticlePubMedGoogle Scholar
- Cabral MD, Teixeira P, Soares D, Leite S, Salles E, Waisman M. Effects of thyroxine replacement on endothelial function and carotid artery intima-media thickness in female patients with mild subclinical hypothyroidism. Clinics (Sao Paulo). 2011;66(8):1321–8.Google Scholar
- Martins RM, Fonseca RH, Duarte MM, Reuters VS, Ferreira MM, Almeida C, et al. Impact of subclinical hypothyroidism treatment in systolic and diastolic cardiac function. Arq Bras Endocrinol Metabol. 2011;55(7):460–7.View ArticlePubMedGoogle Scholar
- Reuters VS, Almeida Cde P, Teixeira Pde F, Vigario Pdos S, Ferreira MM, Castro CL, et al. Effects of subclinical hypothyroidism treatment on psychiatric symptoms, muscular complaints, and quality of life. Arq Bras Endocrinol Metabol. 2012;56(2):128–36.PubMedGoogle Scholar
- Jabbar A, Ingoe L, Pearce S, Zaman A, Razvi S. Thyroxine in acute myocardial infarction (ThyrAMI) - levothyroxine in subclinical hypothyroidism post-acute myocardial infarction: study protocol for a randomised controlled trial. Trials. 2015;16:115.View ArticlePubMedPubMed CentralGoogle Scholar
- Najafi L, Malek M, Hadian A, Ebrahim Valojerdi A, Khamseh ME, Aghili R. Depressive symptoms in patients with subclinical hypothyroidism--the effect of treatment with levothyroxine: a double-blind randomized clinical trial. Endocr Res. 2015;40(3):121–6.View ArticlePubMedGoogle Scholar
- Bukvic B, Zivaljevic V, Sipetic S, Diklic A, Tausanovic K, Stojanovic D, et al. Improved quality of life in hyperthyroidism patients after surgery. J Surg Res. 2015;193(2):724–30.View ArticlePubMedGoogle Scholar
- Ross DS. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. Am J Med. 1993;95(4):385–8.View ArticlePubMedGoogle Scholar
- Watt T, Hegedus L, Groenvold M, Bjorner JB, Rasmussen AK, Bonnema SJ, et al. Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur J Endocrinol. 2010;162(1):161–7.View ArticlePubMedGoogle Scholar
- EuroQol Group--a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam, Netherlands). 1990;16(3):199–208.
- Gunther CM, Burger A, Rickert M, Crispin A, Schulz CU. Grip strength in healthy caucasian adults: reference values. J Hand Surg. 2008;33(4):558–65.View ArticleGoogle Scholar
- Houx PJ, Shepherd J, Blauw GJ, Murphy MB, Ford I, Bollen EL, et al. Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry. 2002;73(4):385–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index. Md State Med J. 1965;14:61–5.PubMedGoogle Scholar
- Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardised Measure of Biological and psychosocial function. JAMA. 1963;185:914–9.View ArticlePubMedGoogle Scholar
- Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.View ArticlePubMedGoogle Scholar
- Wong CK, Lang BH, Lam CL. A systematic review of quality of thyroid-specific health-related quality-of-life instruments recommends ThyPRO for patients with benign thyroid diseases. J Clin Epidemiol. 2016;78:63–72.View ArticlePubMedGoogle Scholar
- EuroQol Group. Barthel Activities of Daily Living (ADL) Index. Occas Pap R Coll Gen Pract. 1993;(59):24.
- Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol. 1981;36(4):428–34.View ArticlePubMedGoogle Scholar
- Winther KH, Watt T, Bjorner JB, Cramon P, Feldt-Rasmussen U, Gluud C, et al. The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial. Trials. 2014;15:115.View ArticlePubMedPubMed CentralGoogle Scholar
- Blum MR, Wijsman LW, Virgini VS, Bauer DC, Den Elzen WPJ, Jukema JW, et al. Subclinical thyroid dysfunction and depressive symptoms among the elderly: a prospective cohort study. Neuroendocrinology. 2016;103(3–4):291–9.PubMedGoogle Scholar
- Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF, et al. Fish intake and risk of incident atrial fibrillation. Circulation. 2004;110(4):368–73.View ArticlePubMedPubMed CentralGoogle Scholar
- Kaleschke G, Hoffmann B, Drewitz I, Steinbeck G, Naebauer M, Goette A, et al. Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. Europace. 2009;11(10):1362–8.View ArticlePubMedGoogle Scholar
- Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040–9.View ArticlePubMedGoogle Scholar